# Harvard Bioscience Inc: overview HBIO · Nasdaq · CIK 1123494 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/hbio.md) · [Financials](/companies/hbio/financials.md) · [Filings](/companies/hbio/filings.md) · [Insiders](/companies/hbio/insiders.md) Latest reported revenue: [$22.7m](/filings/0001171843-26-005425.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001171843-26-005425). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [22.0](/filings/0001171843-25-007099.md) | [24.6 d](/filings/0001171843-26-001548.md) | [21.8](/filings/0001171843-26-003311.md) | [20.5](/filings/0001171843-26-005425.md) | [20.6](/filings/0001171843-25-007099.md) | [23.7 d](/filings/0001171843-26-001548.md) | [20.8](/filings/0001171843-26-003311.md) | [22.7](/filings/0001171843-26-005425.md) | | Gross margin | % | [58.1%](/filings/0001171843-25-007099.md) | [57.1% d](/filings/0001171843-26-001548.md) | [56.0%](/filings/0001171843-26-003311.md) | [56.4%](/filings/0001171843-26-005425.md) | [58.4%](/filings/0001171843-25-007099.md) | [59.7% d](/filings/0001171843-26-001548.md) | [59.0%](/filings/0001171843-26-003311.md) | [55.6%](/filings/0001171843-26-005425.md) | | Operating margin | % | [(8.5%)](/filings/0001171843-25-007099.md) | [0.0% d](/filings/0001171843-26-001548.md) | [(228.1%)](/filings/0001171843-26-003311.md) | [(4.0%)](/filings/0001171843-26-005425.md) | [1.0%](/filings/0001171843-25-007099.md) | [7.2% d](/filings/0001171843-26-001548.md) | [(5.7%)](/filings/0001171843-26-003311.md) | [(4.3%)](/filings/0001171843-26-005425.md) | | Net margin | % | [(21.9%)](/filings/0001171843-25-007099.md) | [0.1% d](/filings/0001171843-26-001548.md) | [(231.2%)](/filings/0001171843-26-003311.md) | [(11.2%)](/filings/0001171843-26-005425.md) | [(6.0%)](/filings/0001171843-25-007099.md) | [(12.0%) d](/filings/0001171843-26-001548.md) | [(16.5%)](/filings/0001171843-26-003311.md) | [(12.8%)](/filings/0001171843-26-005425.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001171843-25-007099.md) | not reported | [(11.42)](/filings/0001171843-26-003311.md) | [(0.52)](/filings/0001171843-26-005425.md) | [(0.03)](/filings/0001171843-25-007099.md) | not reported | [(0.77)](/filings/0001171843-26-003311.md) | [(0.64)](/filings/0001171843-26-005425.md) | | Free cash flow | $m | [(1.7) d](/filings/0001171843-25-007099.md) | [1.4 d](/filings/0001171843-26-001548.md) | [2.5](/filings/0001171843-26-003311.md) | [2.7 d](/filings/0001171843-26-005425.md) | [0.9 d](/filings/0001171843-25-007099.md) | [(0.5) d](/filings/0001171843-26-001548.md) | [(1.1)](/filings/0001171843-26-003311.md) | [(0.4) d](/filings/0001171843-26-005425.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [119](/filings/0001171843-23-001566.md) | [113](/filings/0001171843-24-001239.md) | [112](/filings/0001171843-25-001472.md) | [94.1](/filings/0001171843-26-001548.md) | [86.6](/filings/0001171843-26-001548.md) | | Gross margin | % | [56.9%](/filings/0001171843-23-001566.md) | [53.7%](/filings/0001171843-24-001239.md) | [58.9%](/filings/0001171843-25-001472.md) | [58.2%](/filings/0001171843-26-001548.md) | [57.7%](/filings/0001171843-26-001548.md) | | Operating margin | % | [1.7%](/filings/0001171843-23-001566.md) | [(6.1%)](/filings/0001171843-24-001239.md) | [1.7%](/filings/0001171843-25-001472.md) | [(6.6%)](/filings/0001171843-26-001548.md) | [(56.1%)](/filings/0001171843-26-001548.md) | | Net margin | % | [(0.2%)](/filings/0001171843-23-001566.md) | [(8.4%)](/filings/0001171843-24-001239.md) | [(3.0%)](/filings/0001171843-25-001472.md) | [(13.2%)](/filings/0001171843-26-001548.md) | [(65.5%)](/filings/0001171843-26-001548.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001171843-22-001806.md) | [(0.23)](/filings/0001171843-24-001239.md) | [(0.08)](/filings/0001171843-25-001472.md) | [(0.28)](/filings/0001171843-26-001548.md) | [(1.28)](/filings/0001171843-26-001548.md) | | Free cash flow | $m | [0.1](/filings/0001171843-23-001566.md) | [(0.4)](/filings/0001171843-24-001239.md) | [12.2](/filings/0001171843-25-001472.md) | [(1.2)](/filings/0001171843-26-001548.md) | [5.5](/filings/0001171843-26-001548.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hbio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [WEBER CAPITAL MANAGEMENT LLC /ADV](/funds/1099905.md) | 2026-06-30 | $1.9m | 310,861 | | Reduced −9,176 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.0m | 169,625 | | Added +6,312 | | [CORSAIR CAPITAL MANAGEMENT, L.P.](/funds/1276470.md) | 2026-06-30 | $755.3k | 122,810 | | Reduced −2,000 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $704.5k | 114,545 | | Added +428 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $610.9k | 99,327 | | Reduced −2,100 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $380.3k | 61,834 | | Reduced −392 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $292.5k | 47,555 | | Reduced −11,956 | | [Mink Brook Asset Management LLC](/funds/2052205.md) | 2026-06-30 | $205.2k | 33,369 | | New +33,369 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $200.6k | 32,620 | | Reduced −13,712 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $170.5k | 27,730 | | Unchanged | ## Recent filings [All 940 filings](/companies/hbio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:30 ET | [10-Q](/filings/0001171843-26-005425.md) | Quarterly report, period 2026-06-30 | 0001171843-26-005425 | | 2026-08-11 | 07:00 ET | [8-K](/filings/0001171843-26-005406.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-005406 | | 2026-08-11 | 07:00 ET | [8-K](/filings/0001171843-26-005405.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005405 | | 2026-06-02 | 16:01 ET | [8-K](/filings/0001171843-26-003877.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001171843-26-003877 | | 2026-05-12 | 16:30 ET | [10-Q](/filings/0001171843-26-003311.md) | Quarterly report, period 2026-03-31 | 0001171843-26-003311 | | 2026-05-12 | 07:30 ET | [8-K](/filings/0001171843-26-003271.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-003271 | | 2026-05-12 | 07:30 ET | [8-K](/filings/0001171843-26-003270.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003270 | | 2026-04-21 | 16:56 ET | [DEF 14A](/filings/0001171843-26-002617.md) | Proxy statement, period 2026-06-02 | 0001171843-26-002617 | | 2026-03-23 | 08:00 ET | [SCHEDULE 13D](/filings/0001171843-26-001839.md) | Ownership report, active investor | 0001171843-26-001839 | | 2026-03-17 | 07:30 ET | [8-K](/filings/0001171843-26-001614.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-001614 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001171843-26-001548.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/daa12b1a-983a-4f8a-989f-73bb64308ad5) ## About the filer - CIK: 1123494 - Tickers: HBIO - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.